<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39432616</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>42</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study.</ArticleTitle><Pagination><StartPage>e40075</StartPage><MedlinePgn>e40075</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e40075</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000040075</ELocationID><Abstract><AbstractText>The study aimed to explore the influencing factors after 2 doses of inactivated COVID-19 vaccines (Sinopharm/BBIBP-CorV) in the real world. We conducted a cross-sectional serological study involving 316 volunteers aged ≧ 18 years from 7 vaccination hospitals in the Yubei districts, Yuzhong districts, and Jiulongpo districts of Chongqing. Serum samples were obtained about 1 month after 2 dose vaccination, and Nabs were tested using the pseudovirus-based neutralizing assay. Chi-square or Fisher exact tests were used to analyze the seropositive rates, while the Kruskal-Wallis H or Mann-Whitney U tests were used to analyze differences in Nabs level among stratified groups. Logistic regression analyses were conducted to identify the influencing factors. The results showed that seropositive rates was 76.27% and the GMT was 26.13 (95% CI: 23.03-29.66) after 2 doses of COVID-19 inactivated vaccination. The risk of being seropositive in 18 to 29, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years were 12.808-fold, 8.041-fold, 7.818-fold, 6.275-fold, 1.429-fold compared with the people aged ≥ 70 years (P &lt; .05), and the risk of being seropositive of intervals 15 to 21 and 22 to 28 days were 0.273-fold and 0.286-fold compared with &gt;28 days (P &lt; .05), respectively. In conclusion, age may be a risk factor for reduced antibody production, and longer vaccination intervals-may be a protective factor that increases antibody production. These findings contribute to informing future vaccination strategies.</AbstractText><CopyrightInformation>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0000-7788-5669</Identifier><AffiliationInfo><Affiliation>Expand Program on Immunization, Chongqing Center for Disease Control and Prevention, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jianqiao</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>[Grant number 2022ZDXM030]</GrantID><Agency>Chongqing Medical Scientific Research Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000706269">SARS-CoV-2 inactivated vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432616</ArticleId><ArticleId IdType="pmc">PMC11495710</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000040075</ArticleId><ArticleId IdType="pii">00005792-202410180-00032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, et al. . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Duan K, Zhang Y, et al. . Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426884</ArticleId><ArticleId IdType="pubmed">32789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Zhang Y, Wang Y, et al. . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561304</ArticleId><ArticleId IdType="pubmed">33069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:1–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431125</ArticleId><ArticleId IdType="pubmed">30867162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, et al. . Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, et al. . Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protocols. 2020;15:3699–715.</Citation><ArticleIdList><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Balinsky C, Jani V, Sun P, Williams M, Defang G, Porter KR. Pseudovirus-based assays for the measurement of antibody-mediated neutralization of SARS-CoV-2. Methods Mol Biol. 2022;2452:361–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">35554917</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Borisov O, Kee JJ, et al. . Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Res Sq. 2021;11:23921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671391</ArticleId><ArticleId IdType="pubmed">34907214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Song D, Bai H, et al. . A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J Med Virol. 2017;89:2075–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28786502</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MHG, de Souza TFG, de Carvalho Araújo FM, de Andrade LOM. Dynamics of antibody response to CoronaVac vaccine. J Med Virol. 2022;94:2139–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015561</ArticleId><ArticleId IdType="pubmed">35060174</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes M, Vasconcelos GS, de Melo ACL, et al. . Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: a review. Mol Immunol. 2023;156:148–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998295</ArticleId><ArticleId IdType="pubmed">36921489</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellini R, Venuti A, Pimpinelli F, et al. . Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177433</ArticleId><ArticleId IdType="pubmed">34109307</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: beyond immune senescence. Immun Ageing. 2020;17:1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204009</ArticleId><ArticleId IdType="pubmed">32399058</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145:1309–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198995</ArticleId><ArticleId IdType="pubmed">32386655</ArticleId></ArticleIdList></Reference><Reference><Citation>Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16:442–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7475801</ArticleId><ArticleId IdType="pubmed">31657690</ArticleId></ArticleIdList></Reference><Reference><Citation>Soegiarto G, Wulandari L, Purnomosari D, et al. . Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40:4046–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135674</ArticleId><ArticleId IdType="pubmed">35660034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsunaga T, Ohtaki Y, Seki Y, et al. . The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021;9:e12316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520395</ArticleId><ArticleId IdType="pubmed">34721989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Bai Y, et al. . Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021;31:732–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138844</ArticleId><ArticleId IdType="pubmed">34021265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>